The VA Psilocybin Trial: What Has Been Registered, and What Has Not Been Measured

The VA’s PIVOT trial has not reported any outcome. There is no reported finding of effectiveness, lack of effectiveness, benefit, harm, or safety from this trial in the record reviewed here. This article describes the trial’s registered position as of August 20, 2026; that position can change after that date.

By Cannible Editorial

2026-08-08

This is general information, not individualized medical or treatment advice. Decisions about depression, PTSD, clinical-trial participation, or any other health matter should be discussed with a qualified health care professional.

What the registry records

The study is registered under the acronym PIVOT, or “Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression.” The registry describes it as a multisite, randomized, double-blind, controlled trial sponsored by the VA Office of Research and Development. Its stated purpose is to evaluate the efficacy and risks of psilocybin in U.S. military Veterans with treatment-resistant depression, with or without concurrent PTSD. 1

Allocation: For the first psilocybin administration, participants are randomized under blinded conditions to one of two dose levels. 1

Masking: The trial is described as double-blind, and outcome assessments are conducted by an independent evaluator masked from all treatments. 1

Arms: The registered comparison is between two psilocybin doses at the first administration. One month later, all participants receive the same dose at the second psilocybin visit. The supplied registry material does not describe a placebo arm or a no-treatment arm. 1

Planned enrollment: The supplied registry material does not state the planned number of participants.

Phase: The supplied registry material does not state a clinical-trial phase.

Primary outcome: The supplied registry material does not identify a single primary outcome measure. It states that outcomes are measured by an independent evaluator two and four weeks after each dosing session. 1

Sites and study schedule

The registry lists five study locations: Birmingham VA Medical Center and Tuscaloosa VA Medical Center in Alabama; VA Portland Health Care System in Oregon; Corporal Michael J. Crescenz VA Medical Center in Philadelphia; and the Seattle Division of VA Puget Sound Health Care System in Washington. 1

The registered sequence includes two psilocybin administration sessions. The first session uses the randomized, blinded two-dose comparison; the second occurs one month later, when all participants receive the same dose. Outcome assessments are planned at two and four weeks after each session. The supplied registry material does not provide the trial’s registration date, launch date, recruitment dates, completion date, or estimated date for any of these activities. 1

What has not been measured or reported

As of August 20, 2026, the record supplied for this article reports no trial results. Accordingly, it does not establish whether the intervention changed depression symptoms, whether effects differed between the registered dose arms, whether outcomes differed for Veterans with or without concurrent PTSD, or whether the intervention was safe or tolerable in this study. 1

The VA’s public description says the study is intended to assess depression before and after treatment, side-effect tolerability, and patient-reported depression. Those are planned areas of assessment, not findings. The supplied material does not provide numerical results, participant-level results, a completed analysis, or a safety finding. 2 1

The surrounding federal context is separate from trial evidence

A presidential document titled “Accelerating Medical Treatments for Serious Mental Illness” was signed on April 18, 2026, and published on April 22, 2026. It directs federal agencies toward actions involving psychedelic-drug research, data sharing, review prioritization, and possible future processes for specific products under the conditions described in that document. Those directives do not constitute a result from the VA’s PIVOT trial. 3

Separately, an FDA notice announces a public hearing and request for comments about the potential future therapeutic use of psychedelic drugs. The hearing is scheduled for September 14, 2026, and comments are accepted until October 5, 2026. As of August 20, 2026, those are scheduled procedural events, not a completed hearing or a final agency action. They also do not change the fact that PIVOT has reported no outcome. 4

Bottom line

What is registered is a multisite, randomized, double-blind comparison of two psilocybin dose levels for Veterans with treatment-resistant depression, including participants with or without concurrent PTSD, followed by prespecified post-session assessments. What is not available in the supplied record is the trial’s phase, planned enrollment, named primary outcome measure, study dates, or any outcome. This trial concerns psilocybin, not cannabis, and it provides no basis for conclusions about cannabis, cannabis policy, or cannabis scheduling. 1